A single, continuous metric to define tiered serum neutralization potency against HIV
Abstract
HIV-1 Envelope (Env) variants are grouped into tiers by their neutralization-sensitivity phenotype. This helped to recognize that tier 1 neutralization responses can be elicited readily, but do not protect against new infections. Tier 3 viruses are the least sensitive to neutralization. Because most circulating viruses are tier 2, vaccines that elicit neutralization responses against them are needed. While tier classification is widely used for viruses, a way to rate serum or antibody neutralization responses in comparable terms is needed. Logistic regression of neutralization outcomes summarizes serum or antibody potency on a continuous, tier-like scale. It also tests significance of the neutralization score, to indicate cases where serum response does not depend on virus tiers. The method can standardize results from different virus panels, and could lead to high-throughput assays, which evaluate a single serum dilution, rather than a dilution series, for more efficient use of limited resources to screen samples from vaccinees.
- Authors:
-
[1];
[2];
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States); New Mexico Consortium, Los Alamos (United States)
- Duke Univ., Durham, NC (United States). Medical Center, Dept. of Surgery
- National Inst. of Health (NIH), Bethesda, MD (United States). Vaccine Research Center, National Inst. of Allergy and Infectious Diseases
- Publication Date:
- Research Org.:
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Sponsoring Org.:
- USDOE; National Institutes of Health (NIH); Bill and Melinda Gates Foundation
- Contributing Org.:
- Duke University
- OSTI Identifier:
- 1419748
- Report Number(s):
- LA-UR-16-29342
Journal ID: ISSN 2050-084X
- Grant/Contract Number:
- AC52-06NA25396
- Resource Type:
- Accepted Manuscript
- Journal Name:
- eLife
- Additional Journal Information:
- Journal Volume: 7; Journal ID: ISSN 2050-084X
- Publisher:
- eLife Sciences Publications, Ltd.
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES; Biological Science
Citation Formats
Hraber, Peter Thomas, Korber, Bette Tina Marie, Wagh, Kshitij, Montefiori, David, and Roederer, Mario. A single, continuous metric to define tiered serum neutralization potency against HIV. United States: N. p., 2018.
Web. doi:10.7554/eLife.31805.
Hraber, Peter Thomas, Korber, Bette Tina Marie, Wagh, Kshitij, Montefiori, David, & Roederer, Mario. A single, continuous metric to define tiered serum neutralization potency against HIV. United States. doi:10.7554/eLife.31805.
Hraber, Peter Thomas, Korber, Bette Tina Marie, Wagh, Kshitij, Montefiori, David, and Roederer, Mario. Fri .
"A single, continuous metric to define tiered serum neutralization potency against HIV". United States. doi:10.7554/eLife.31805. https://www.osti.gov/servlets/purl/1419748.
@article{osti_1419748,
title = {A single, continuous metric to define tiered serum neutralization potency against HIV},
author = {Hraber, Peter Thomas and Korber, Bette Tina Marie and Wagh, Kshitij and Montefiori, David and Roederer, Mario},
abstractNote = {HIV-1 Envelope (Env) variants are grouped into tiers by their neutralization-sensitivity phenotype. This helped to recognize that tier 1 neutralization responses can be elicited readily, but do not protect against new infections. Tier 3 viruses are the least sensitive to neutralization. Because most circulating viruses are tier 2, vaccines that elicit neutralization responses against them are needed. While tier classification is widely used for viruses, a way to rate serum or antibody neutralization responses in comparable terms is needed. Logistic regression of neutralization outcomes summarizes serum or antibody potency on a continuous, tier-like scale. It also tests significance of the neutralization score, to indicate cases where serum response does not depend on virus tiers. The method can standardize results from different virus panels, and could lead to high-throughput assays, which evaluate a single serum dilution, rather than a dilution series, for more efficient use of limited resources to screen samples from vaccinees.},
doi = {10.7554/eLife.31805},
journal = {eLife},
number = ,
volume = 7,
place = {United States},
year = {2018},
month = {1}
}
Search WorldCat to find libraries that may hold this journal